# US 11,026,971 B2 · Methods and treatment of trauma adverse events with oxygen reduced blood

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,026,971 B2
- Document ID: US11026971B2
- Status: Granted
- Kind: B2
- Application number: 16/903,108
- Filed: 2020-06-16
- Published: 2020-12-03
- Granted: 2021-06-08
- Earliest claimed: 2017-05-19
- Assignees: Hemanext Inc.
- Applicants: Hemanext Inc.
- Inventors: Andrew Dunham; Tatsuro Yoshida
- Web page: https://patentgrep.com/patent/US11026971B2

## CPC

- A61K 35/14: Blood; Artificial blood (perfluorocarbons A61K31/02; umbilical cord blood A61K35/51; haemoglobin A61K38/42)
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/02: Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Methods for the reversal of hemorrhagic shock or hemorrhagic trauma. Methods for restoring mean arterial pressure to a normal range and reducing trauma adverse risks in a patient through the administration of oxygen reduced blood compositions.

## Claims

### Claim 1

A method of reducing the risk of developing a hemorrhagic trauma adverse event in a hemorrhagic trauma subject in need thereof comprising administering stored oxygen reduced blood to a subject having hemorrhagic trauma, said stored oxygen reduced blood comprising a blood product having a reduced oxygen saturation level prior to storage for a storage period, wherein said hemorrhagic trauma adverse event is liver injury and said risk is reduced relative to a patient receiving conventionally stored blood.

### Claim 2 (depends on 1)

The method of claim 1, wherein said hemorrhagic trauma subject in need thereof comprises increased levels of liver enzyme aspartate aminotransferase (AST) prior to said administering.

### Claim 3 (depends on 1)

The method of claim 1, wherein said hemorrhagic trauma subject in need thereof comprises increased levels of liver enzyme alanine aminotransferase (ALT) prior to said administering.

### Claim 4 (depends on 1)

The method of claim 1, wherein said hemorrhagic trauma subject in need thereof comprises decreased hematocrit prior to said administering.

### Claim 5 (depends on 1)

The method of claim 1, wherein said hemorrhagic trauma subject in need thereof comprises an increased lactate level prior to said administering.

### Claim 6 (depends on 1)

The method of claim 1, wherein said stored oxygen reduced blood is depleted to an oxygen saturation of 20% or less prior to said storage period.

### Claim 7 (depends on 1)

The method of claim 1, wherein said stored oxygen reduced blood comprises an oxygen saturation of 20% or less during said storage period.

### Claim 8 (depends on 1)

The method of claim 1, wherein said oxygen reduced blood is also carbon dioxide reduced.

### Claim 9 (depends on 1)

The method of claim 1, wherein said storage period is up to 42 days.

### Claim 10 (depends on 2)

The method of claim 2, wherein said increased AST level is reduced by at least 5% after said administering relative to a patient receiving conventionally stored blood.

### Claim 11 (depends on 3)

The method of claim 3, wherein said increased ALT level is reduced by at least 5% after said administering relative to a patient receiving conventionally stored blood.

### Claim 12 (depends on 5)

The method of claim 5, wherein said increased lactate level is reduced to between 0.5 and 2.5 mmol/L after said administering.

### Claim 13

A method of reducing the risk of developing liver damage in a hemorrhagic trauma subject in need thereof comprising administering stored oxygen reduced blood to a subject having hemorrhagic trauma, said stored oxygen reduced blood comprising a blood product having a reduced oxygen saturation level prior to storage for a storage period, wherein said hemorrhagic trauma subject has increased levels of aspartate aminotransferase (AST), increased levels of alanine aminotransferase (ALT), or both AST and ALT and said risk of liver damage is reduced relative to a patient receiving conventionally stored blood.

### Claim 14 (depends on 13)

The method of claim 13, wherein said increased AST level is reduced by at least 5% after said administering relative to a patient receiving conventionally stored blood.

### Claim 15 (depends on 13)

The method of claim 13, wherein said increased ALT level is reduced by at least 5% after said administering relative to a patient receiving conventionally stored blood.

### Claim 16 (depends on 13)

The method of claim 13, wherein said stored oxygen reduced blood is depleted to an oxygen saturation of 20% or less prior to said storage period.

### Claim 17 (depends on 13)

The method of claim 13, wherein said stored oxygen reduced blood comprises an oxygen saturation of 20% or less during said storage period.

### Claim 18 (depends on 13)

The method of claim 13, wherein said oxygen reduced blood is also carbon dioxide reduced.

### Claim 19 (depends on 14)

The method of claim 14, wherein said storage period is up to 42 days.

### Claim 20 (depends on 14)

The method of claim 14, wherein said increased AST level is reduced by at least 10% after said administering relative to a patient receiving conventionally stored blood.

### Claim 21 (depends on 15)

The method of claim 15, wherein said increased ALT level is reduced by at least 10% after said administering relative to a patient receiving conventionally stored blood.